UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000006514 |
|---|---|
| Receipt number | R000007725 |
| Scientific Title | Phase II trial of irinotecan, paclitaxel plus bevacizumab for previously untreated patients with non-squamous and non-small cell lung cancer, detected the over-expression of ERCC1 by EBUS-GS. |
| Date of disclosure of the study information | 2011/10/12 |
| Last modified on | 2022/06/09 16:32:32 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2011/10/10 20:52:48 | ||
| 2 | Update | 2013/10/10 09:30:17 | TEL Last name of contact person Last name of contact person TEL Tel1 |
|
| 3 | Update | 2014/10/14 12:02:11 | Recruitment status |
|
| 4 | Update | 2015/04/10 15:23:26 | Recruitment status |
|
| 5 | Update | 2016/10/13 11:41:35 | Name of primary person or sponsor Organization |
|
| 6 | Update | 2017/11/20 09:00:37 | Recruitment status |
|
| 7 | Update | 2022/06/08 08:52:03 | Date of IRB Last follow-up date Date analysis concluded |
|
| 8 | Update | 2022/06/09 16:03:46 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 9 | Update | 2022/06/09 16:32:32 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
